SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Aquestive Therapeutics, Inc.– AQST

Friday, 05. March 2021 18:07

NEW YORK, March 05, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) from December 2, 2019 through September 25, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aquestive Therapeutics, Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email for information on the class action.

According to the lawsuit,  defendants made false and/or misleading statements and/or failed to disclose that: data included in the Libervant Buccal Film for the management of seizure clusters (“Libervant”) New Drug Application (“NDA”) submission showed a lower drug exposure level than desired for certain weight groups; the foregoing significantly decreased the Libervant NDA’s approval prospects; as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Libervant NDA in its current form; and as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than April 30, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938 

Primary Logo

Related Links: 
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.